The status of Her2 amplification and Kras mutations in mucinous ovarian carcinoma

Jayson GC et al. remarked in Lancet that nearly 100% of mucinous ovarian cancer cases have Kras mutation as well as a high frequency of Her2 amplification. Using the Abbott PathVysion Her2 DNA Probe Kit and Kras mutant-enriched PCR Kits (FemtoPath®), 21 samples of primary ovarian mucinous cystadenoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Kuang-Leei, Lee, Ming-Yung, Chao, Wan-Ru, Han, Chih-Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5192568/
https://www.ncbi.nlm.nih.gov/pubmed/28031051
http://dx.doi.org/10.1186/s40246-016-0096-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5192568/
https://www.ncbi.nlm.nih.gov/pubmed/28031051
http://dx.doi.org/10.1186/s40246-016-0096-9

Ejemplares similares